News

A Phase 2a clinical trial of AstraZeneca’s experimental therapy mitiperstat is now recruiting adults with moderate to severe chronic obstructive pulmonary disease (COPD) at a study site in Choctaw, Oklahoma. The Care Access research site is among nearly 20 study centers in the U.S., located across 11…

Pulmonary (lung) rehabilitation nearly halves the odds of people with chronic obstructive pulmonary disease (COPD) experiencing an exacerbation, and it also cuts the risk of dying by about one-third, a study in Korea found. The study, “Pulmonary Rehabilitation Is Associated With Decreased Exacerbation and Mortality in Patients With…

Scientists at NextCure have developed a monoclonal antibody targeting the protein VSTM-1, which the company hopes to develop as a treatment for inflammatory lung disorders such as chronic obstructive pulmonary disease (COPD). “We believe we have a real opportunity to change the standard of care in…

Yupelri (revefenacin) is not superior to Spiriva (tiotropium) at improving lung function in adults with severe chronic obstructive pulmonary disease (COPD), according to data from a Phase 4 clinical trial. The head-to-head study, called PIFR-2 (NCT05165485) and sponsored by Yupelri’s co-developers Theravance Biopharma and…

Two international Phase 3 clinical trials testing the investigational antibody itepekimab in people with chronic obstructive pulmonary disease (COPD) are continuing to enroll patients — specifically, former smokers — at hundreds of centers worldwide, with several new sites recently opened in the U.S. All of the new sites are…

The number of people worldwide with chronic obstructive pulmonary disease (COPD) is predicted to increase by 23% in three decades, amounting to nearly 600 million patients by 2050, according to a new study. The largest increase, by nearly 50%, is projected to be among women and people living in…

Treatment with Dupixent (dupilumab) — approved in the U.S. for five inflammatory conditions, to date — once again resulted in significantly fewer exacerbations, or periods of sudden symptom worsening, among people with moderate to severe chronic obstructive pulmonary disease (COPD) in the second of two similarly designed Phase 3…

Long-term treatment with Olympus’ Spiration Valve System (SVS) safely led to sustained improvements in lung function — and in life quality — among people with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). That’s according to two-year follow-up data from the EMPROVE trial, which had tested…

Treatment with the anti-inflammatory medication eblasakimab opened the airways of lung samples from people with chronic obstructive pulmonary disorder (COPD) in laboratory experiments. The findings were shared by Aslan Pharmaceuticals, the company that’s developing eblasakimab, in an oral presentation at the Dermatology Drug Development Summit, held recently in…

The American Lung Association has launched an initiative that has as its goal improving the quality of life of people who’ve been living with chronic obstructive pulmonary disease (COPD) for at least a decade. The “COPD for…